184 related articles for article (PubMed ID: 3359402)
1. Chemotherapy versus chemotherapy with intralymphatic tumor cell vaccine in canine lymphoma.
Jeglum KA; Young KM; Barnsley K; Whereat A
Cancer; 1988 May; 61(10):2042-50. PubMed ID: 3359402
[TBL] [Abstract][Full Text] [Related]
2. In vitro immune monitoring of antibody response in dogs given chemoimmunotherapy for lymphoma.
Jeglum KA; Winters WD; Young KM
Am J Vet Res; 1989 Apr; 50(4):488-92. PubMed ID: 2712415
[TBL] [Abstract][Full Text] [Related]
3. Intralymphatic autochthonous tumor cell vaccine in canine lymphoma.
Jeglum KA; Young KM; Barnsley K; Whereat A; McGrath D; Hutson C
J Biol Response Mod; 1986 Apr; 5(2):168-75. PubMed ID: 3734843
[TBL] [Abstract][Full Text] [Related]
4. A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma.
Zemann BI; Moore AS; Rand WM; Mason G; Ruslander DM; Frimberger AE; Wood CA; L'Heureux DA; Gliatto J; Cotter SM
J Vet Intern Med; 1998; 12(6):465-70. PubMed ID: 9857340
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP-MA) for the treatment of canine lymphoma.
Daters AT; Mauldin GE; Mauldin GN; Brodsky EM; Post GS
Vet Comp Oncol; 2010 Mar; 8(1):11-22. PubMed ID: 20230577
[TBL] [Abstract][Full Text] [Related]
6. Treatment of canine lymphoma with COPLA/LVP.
Boyce KL; Kitchell BE
J Am Anim Hosp Assoc; 2000; 36(5):395-403. PubMed ID: 10997514
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of L-asparaginase: polyethylene glycol conjugate versus native L-asparaginase combined with chemotherapy. A randomized double-blind study in canine lymphoma.
MacEwen EG; Rosenthal RC; Fox LE; Loar AS; Kurzman ID
J Vet Intern Med; 1992; 6(4):230-4. PubMed ID: 1522554
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma.
Moore AS; Cotter SM; Rand WM; Wood CA; Williams LE; London CA; Frimberger AE; L'Heureux DA
J Vet Intern Med; 2001; 15(4):348-54. PubMed ID: 11467592
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995).
Valerius KD; Ogilvie GK; Mallinckrodt CH; Getzy DM
J Am Vet Med Assoc; 1997 Feb; 210(4):512-6. PubMed ID: 9040837
[TBL] [Abstract][Full Text] [Related]
10. Is maintenance chemotherapy appropriate for the management of canine malignant lymphoma?
Hahn KA; Richardson RC; Teclaw RF; Cline JM; Carlton WW; DeNicola DB; Bonney PL
J Vet Intern Med; 1992; 6(1):3-10. PubMed ID: 1548624
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a multidrug chemotherapy protocol (ACOPA II) in dogs with lymphoma.
Myers NC; Moore AS; Rand WM; Gliatto J; Cotter SM
J Vet Intern Med; 1997; 11(6):333-9. PubMed ID: 9470157
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of asparaginase administered subcutaneously versus intramuscularly for treatment of multicentric lymphoma in dogs receiving doxorubicin.
Valerius KD; Ogilvie GK; Fettman MJ; Walton JA; Richardson K; Powers BE; McNiel EA; Rogers QR
J Am Vet Med Assoc; 1999 Feb; 214(3):353-6. PubMed ID: 10023395
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of factors associated with second remission in dogs with lymphoma undergoing retreatment with a cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol: 95 cases (2000-2007).
Flory AB; Rassnick KM; Erb HN; Garrett LD; Northrup NC; Selting KA; Phillips BS; Locke JE; Chretin JD
J Am Vet Med Assoc; 2011 Feb; 238(4):501-6. PubMed ID: 21320021
[TBL] [Abstract][Full Text] [Related]
14. Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol.
Simon D; Nolte I; Eberle N; Abbrederis N; Killich M; Hirschberger J
J Vet Intern Med; 2006; 20(4):948-54. PubMed ID: 16955821
[TBL] [Abstract][Full Text] [Related]
15. Cytosine arabinoside in addition to VCAA-based protocols for the treatment of canine lymphoma with bone marrow involvement: does it make the difference?
Marconato L; Bonfanti U; Stefanello D; Lorenzo MR; Romanelli G; Comazzi S; Zini E
Vet Comp Oncol; 2008 Jun; 6(2):80-9. PubMed ID: 19178667
[TBL] [Abstract][Full Text] [Related]
16. Thirteen-week dose-intensifying simultaneous combination chemotherapy protocol for malignant lymphoma in dogs.
Zenker I; Meichner K; Steinle K; Kessler M; Hirschberger J
Vet Rec; 2010 Nov; 167(19):744-8. PubMed ID: 21257510
[TBL] [Abstract][Full Text] [Related]
17. Ventricular fractional shortening in 108 dogs with malignant lymphoma undergoing chemotherapy with a cyclic combination protocol including doxorubicin.
Tater G; Eberle N; Hungerbuehler S; Joetzke A; Nolte I; Wess G; Betz D
Tierarztl Prax Ausg K Kleintiere Heimtiere; 2012; 40(4):261-6. PubMed ID: 22911257
[TBL] [Abstract][Full Text] [Related]
18. Canine lymphoma.
Madewell BR
Vet Clin North Am Small Anim Pract; 1985 Jul; 15(4):709-22. PubMed ID: 2412330
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy-induced neutropenia is associated with prolonged remission duration and survival time in canine lymphoma.
Wang SL; Lee JJ; Liao AT
Vet J; 2015 Jul; 205(1):69-73. PubMed ID: 26004824
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the results of a L-asparaginase-based continuous chemotherapy protocol versus a short doxorubicin-based induction chemotherapy protocol in dogs with malignant lymphoma.
Piek CJ; Rutteman GR; Teske E
Vet Q; 1999 Apr; 21(2):44-9. PubMed ID: 10321012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
